Stayble Therapeutics: Publication of year-end report 2021
February 2022 RegulatoriskStayble Therapeutics AB (”Stayble” or the ”Company”) published its year-end report for the period January 2021 – December 2021 today. The report (in Swedish) is available as an attached document to this press release and on the Company’s website (Stayble Therapeutics (https://staybletherapeutics.com/investor-relations/financial-reports/)).
Highlights during the fourth quarter (October – December 2021)
- Stayble presented interim data from the ongoing phase 2b study and announced that the patient recruitment is still affected by the Covid-19 and that study results can be presented in 2023.
Highlights after the end of the period
- No significant events that have had an impact on Stayble Therapeutics’ financial position occurred after the period.
For more information
Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397